meta
|
evidence
COVID-19
Living systematic review and meta-analysis
adjuvant therapies
anti-inflammatoty and immuno-therapy
antiandrogenic
antiviral and associated therapy
control
Drugs for acid related disorders
miscellaneous
2-deoxy-D-glucose (2-DG)
acetylcysteine
alpha lipoic acid
anti-CK2
Aspirin
aviptadil
BLD-2660 (calpain inhibitor)
calcium channel blocker
camostat mesilate
Cannabidiol
continuous positive airway pressure (CPAP)
cytokine adsorption
diammonium glycyrrhizinate
dipyridamol
dornase alfa
expectorants and mucolytics
honey
kinin-kallikrein inhibitors
melatonin
mouthrise and gargling agents
mouthrinses
N-Acetylcysteine
nasal spray
nasal spray containing Iota-Carrageenan
natural killer (NK) cells
nicotin
nigella sativa oil
nitric oxide (gas Inhalation or releasing solution)
omega-3 Polyunsaturated Fatty Acids
ozonated autohemotherapy
plasma exchange
povidone-iodine
previfenon (EGCG)
prostacyclin
PUL-042 inhalation solution
pyridostigmine
radiotherapy
sabizabulin
sildenafil
triiodothyronine (T3)
Oral antidiabetic drugs
Renin-angiotensin-system-acting agents
vaccines
Vitamins
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention
Meta-analysis results for all treatments
Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
Treament
Trials
Summary
Endpoints
core analysis (OBS if no RCT)
RCTs only
all (RCT+OBS)
Demonstrated or suggested benefit
Inconclusive results
Uncertain results
Safety results
2-deoxy-D-glucose (2-DG)
0
-
-
-
-
acetylcysteine
0
-
-
-
-
alpha lipoic acid
0
-
-
-
-
anti-CK2
0
-
-
-
-
Aspirin
0
-
-
-
-
aviptadil
0
-
-
-
-
BLD-2660 (calpain inhibitor)
0
-
-
-
-
calcium channel blocker
0
-
-
-
-
camostat mesilate
0
-
-
-
-
Cannabidiol
0
-
-
-
-
continuous positive airway pressure (CPAP)
0
-
-
-
-
cytokine adsorption
0
-
-
-
-
diammonium glycyrrhizinate
0
-
-
-
-
dipyridamol
0
-
-
-
-
dornase alfa
0
-
-
-
-
expectorants and mucolytics
0
-
-
-
-
honey
0
-
-
-
-
kinin-kallikrein inhibitors
0
-
-
-
-
melatonin
0
-
-
-
-
mouthrise and gargling agents
0
-
-
-
-
N-Acetylcysteine
0
-
-
-
-
nasal spray
0
-
-
-
-
natural killer (NK) cells
0
-
-
-
-
nicotin
0
-
-
-
-
nigella sativa oil
0
-
-
-
-
nitric oxide (gas Inhalation or releasing solution)
0
-
-
-
-
omega-3 Polyunsaturated Fatty Acids
0
-
-
-
-
ozonated autohemotherapy
0
-
-
-
-
plasma exchange
0
-
-
-
-
povidone-iodine
0
-
-
-
-
previfenon (EGCG)
0
-
-
-
-
prostacyclin
0
-
-
-
-
PUL-042 inhalation solution
0
-
-
-
-
pyridostigmine
0
-
-
-
-
radiotherapy
0
-
-
-
-
sabizabulin
0
-
-
-
-
sildenafil
0
-
-
-
-
triiodothyronine (T3)
0
-
-
-
-